A rare-cannabinoid-focused pharmaceutical company in Canada has released the results of its latest study.
On Tuesday, Vancouver-based InMed Pharmaceuticals Inc. announced that its peer-reviewed “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences.
InMed says the scientific study examines how tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA), and cannabichromene (CBC) bioactivity may be useful for treating skin conditions.
“This study represents the first systematic analysis of the effects of the rare cannabinoids THCV, CBC, CBGA, and CBD on the major endocannabinoid system elements using human kertainocytes,” says InMed Scientific Advisor Dr. Mauro Maccarrone. “These initial observations should be considered when exploring the therapeutic potential of rare cannabinoids for the treatment of human skin disease.”
InMed says researchers used an in vitro human keratinocyte model to study interactions between cannabinoids, receptors, and other endocannabinoid system elements.
Study results showed that each cannabinoid had distinct biological activity in the endocannabinoid system.
InMed says THCV performed particularly well as a cannabinoid receptor 1 (CB1) antagonist, with a high affinity for the human transient receptor vanilloid 1 (TRPV1).
InMed says CBC performed similarly, but to a lesser extent.
According to InMed, the results support further rare cannabinoid research and their potential effects on skin conditions.
InMed Senior VP of Preclinical Research and Development Dr. Eric Hsu says the study provides important scientific research that examines rare cannabinoids’ distinctly different physiological effects.
“As we continue to expand our portfolio of rare cannabinoids, including THCV and CBC, evidence-based research is imperative to improving our understanding of their biological activity,” says Dr. Hsu. “There is growing interest in the potential benefits of rare cannabinoids, and this study represents InMed’s commitment to contributing to the body of research of rare cannabinoids.”